Karuna Therapeutics Inc
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
About KRTX
Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its pipeline built on the therapeutic potential of its lead product candidate, KarXT (xanomeline-trospium), an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. It is developing KarXT for the treatment of acute psychosis in adults with schizophrenia, and for the treatment of psychosis in Alzheimer's disease. Its pipeline also includes clinical-stage candidate KAR-2618, a TRPC4/5 inhibitor for the treatment of mood and anxiety disorders, and pre-clinical muscarinic, TRPC4/5 and target-agnostic compounds for the treatment of psychiatric and neurological conditions.
Buy US stocks in Australia starting with KRTX. Open an account and start investing today!
-
-
-
-
-
-
-
-
-
Ready to start your investing journey with Stake?
Open an accountKRTX FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in KRTX
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in KRTX
on Stake
Buy KRTX from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of KRTX from only US$10 with fractional shares